A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

A. Harrison, Stephen; Bédossa, Pierre; D. Guy, Cynthia; M. Schattenberg, Jörn; Loomba, Rohit; Taub, Rebecca; Labriola, Dominic; E. Moussa, Sam; Neff, Guy; E. Rinella, Mary; M. Anstee, Quentin; F. Abdelmalek, Manal; M. Younossi, Zobair; J. Baum, Seth; Francque, Sven; Charlton, Michael; N. Newsome, Philip; Lanthier, Nicolas; Schiefke, Ingolf; Mangia, Alessandra; M. Pericàs, Juan; Patil, Rashmee; J. Sanyal, Arun; Noureddin, Mazen; B. Bansal, Meena; Alkhouri, Naim; Castéra, Laurent; Rudraraju, Madhavi; Ratziu, Vlad

doi:10.1056/nejmoa2309000

Public

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Published in New England Journal of Medicine • Feb 7, 2024

Authors:

Stephen A. Harrison

Pierre Bédossa

Cynthia D. Guy

Abstract

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase ...

Subject

Internal medicine

Placebo

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!